BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 11907489)

  • 21. The PUVA-turban as a new option of applying a dilute psoralen solution selectively to the scalp of patients with alopecia areata.
    Behrens-Williams SC; Leiter U; Schiener R; Weidmann M; Peter RU; Kerscher M
    J Am Acad Dermatol; 2001 Feb; 44(2):248-52. PubMed ID: 11174382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Differentiation of the antipsoriatic and phototoxic effectiveness of topical PUVA therapy].
    Meffert H; Rowe E; Miehe M; Sönnichsen N
    Hautarzt; 1986 Feb; 37(2):90-3. PubMed ID: 3957667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy.
    Shephard SE; Panizzon RG
    Dermatology; 1999; 199(2):106-12. PubMed ID: 10559574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of skin concentrations following topical versus oral corticosteroid treatment: reconsidering the treatment of common inflammatory dermatoses.
    McClain RW; Yentzer BA; Feldman SR
    J Drugs Dermatol; 2009 Dec; 8(12):1076-9. PubMed ID: 20027934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma levels of 8-methoxypsoralen following oral or bath-water treatment.
    Thomas SE; O'Sullivan J; Balac N
    Br J Dermatol; 1991 Jul; 125(1):56-8. PubMed ID: 1873204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma levels of 8-methoxypsoralen after topical paint PUVA.
    Pham CT; Koo JY
    J Am Acad Dermatol; 1993 Mar; 28(3):460-6. PubMed ID: 8445063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High plasma levels of 8-methoxypsoralen following bath water delivery in dermatological patients.
    Kappes UP; Barta U; Merkel U; Balogh A; Elsner P
    Skin Pharmacol Appl Skin Physiol; 2003; 16(5):305-12. PubMed ID: 12907835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Skin photosensitizing and Langerhans' cell depleting activity of topical (bath) PUVA therapy: comparison of trimethylpsoralen and 8-methoxypsoralen.
    Koulu L; Jansén CT
    Acta Derm Venereol; 1983; 63(2):137-41. PubMed ID: 6189328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis.
    Collins P; Rogers S
    Br J Dermatol; 1992 Oct; 127(4):392-5. PubMed ID: 1419760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bath PUVA and psoriasis: is a milder treatment a worse treatment?
    Delrosso G; Bornacina C; Farinelli P; Bellinzona F; Leigheb G; Colombo E
    Dermatology; 2008; 216(3):191-3. PubMed ID: 18182808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term efficacy of PUVA treatment in lichen planus: comparison of oral and external methoxsalen regimens.
    Helander I; Jansén CT; Meurman L
    Photodermatol; 1987 Oct; 4(5):265-8. PubMed ID: 3697349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Skin pigmentation as a predictor of minimal phototoxic dose after oral methoxsalen.
    Bech-Thomsen N; Angelo HR; Wulf HC
    Arch Dermatol; 1994 Apr; 130(4):464-8. PubMed ID: 8166483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phototoxicity and antipsoriatic effect of a topical methoxypsoralen solution in relation to the application time.
    Meffert H; Andersen KE; Sönnichsen N
    Photodermatol; 1984 Aug; 1(4):191-4. PubMed ID: 6531293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variation in 8-methoxypsoralen profiles during long-term psoralen plus ultraviolet A therapy and correlations between serum 8-methoxypsoralen levels and chromametric parameters.
    Marrakchi S; Decloquement L; Pollet P; Briand G; Loesche C; Bocquet JL; Degand P; Thomas P
    Photodermatol Photoimmunol Photomed; 1991 Oct; 8(5):206-11. PubMed ID: 1822684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Influence of retinoids on the bioavailability of methoxy-8-psoralen].
    Beani JC; Bonnot D; Berthod F; Boitard M; Reymond JL; Beriel H; Amblard P
    Ann Dermatol Venereol; 1991; 118(4):273-5. PubMed ID: 2069337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kinetics of photosensitivity in bath-PUVA photochemotherapy.
    Gruss C; Behrens S; Reuther T; Husebo L; Neumann N; Altmeyer P; Lehmann P; Kerscher M
    J Am Acad Dermatol; 1998 Sep; 39(3):443-6. PubMed ID: 9738780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phototesting in bath-PUVA: marked reduction of 8-methoxypsoralen (8-MOP) activity within one hour after an 8-MOP bath.
    Schempp CM; Schöpf E; Simon JC
    Photodermatol Photoimmunol Photomed; 1996 Jun; 12(3):100-2. PubMed ID: 8956358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma levels of 8-methoxypsoralen following PUVA-bath photochemotherapy.
    von Kobyletzki G; Hoffmann K; Kerscher M; Altmeyer P
    Photodermatol Photoimmunol Photomed; 1998; 14(3-4):136-8. PubMed ID: 9779504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic comparison of seven 8-methoxypsoralen brands.
    Menne T; Andersen KE; Larsen E; Solgaard P
    Acta Derm Venereol; 1981; 61(2):137-40. PubMed ID: 6165189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of tissue and plasma levels of ibuprofen after oral and topical administration.
    Dominkus M; Nicolakis M; Kotz R; Wilkinson FE; Kaiser RR; Chlud K
    Arzneimittelforschung; 1996 Dec; 46(12):1138-43. PubMed ID: 9006788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.